Details for New Drug Application (NDA): 208975
✉ Email this page to a colleague
NDA 208975 describes DOXERCALCIFEROL, which is a drug marketed by Avet, Hikma, Rising, Alembic, Amneal, Epic Pharma Llc, Eugia Pharma, Gland Pharma Ltd, Hospira, Lupin Ltd, Meitheal, Sandoz, and Sun Pharm, and is included in sixteen NDAs. It is available from nine suppliers. Additional details are available on the DOXERCALCIFEROL profile page.
The generic ingredient in DOXERCALCIFEROL is doxercalciferol. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the doxercalciferol profile page.
The generic ingredient in DOXERCALCIFEROL is doxercalciferol. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the doxercalciferol profile page.
Summary for 208975
| Tradename: | DOXERCALCIFEROL |
| Applicant: | Amneal |
| Ingredient: | doxercalciferol |
| Patents: | 0 |
Suppliers and Packaging for NDA: 208975
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DOXERCALCIFEROL | doxercalciferol | INJECTABLE;INJECTION | 208975 | ANDA | Amneal Pharmaceuticals LLC | 70121-1408 | 70121-1408-5 | 50 VIAL, MULTI-DOSE in 1 CARTON (70121-1408-5) / 2 mL in 1 VIAL, MULTI-DOSE (70121-1408-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 4MCG/2ML (2MCG/ML) | ||||
| Approval Date: | May 24, 2017 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
